UBcare Valuation

Is A032620 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of A032620 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: A032620 (₩3520) is trading above our estimate of fair value (₩1298.81)

Significantly Below Fair Value: A032620 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for A032620?

Key metric: As A032620 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for A032620. This is calculated by dividing A032620's market cap by their current revenue.
What is A032620's PS Ratio?
PS Ratio	1x
Sales	₩170.58b
Market Cap	₩178.61b

A032620 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	1x
Enterprise Value/EBITDA	21.4x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does A032620's PS Ratio compare to its peers?

The above table shows the PS ratio for A032620 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	12.1x
A071200 INFINITT Healthcare	1.1x	n/a	₩112.3b
A311690 CJ Bioscience	25.4x	n/a	₩124.6b
A384470 Coreline Soft	20.3x	n/a	₩89.8b
A099750 ezCaretech	1.5x	n/a	₩110.0b
A032620 UBcare	1x	n/a	₩178.6b

Price-To-Sales vs Peers: A032620 is good value based on its Price-To-Sales Ratio (1x) compared to the peer average (12.1x).

Price to Sales Ratio vs Industry

How does A032620's PS Ratio compare vs other companies in the Asian Healthcare Services Industry?

5 Companies	Price / Sales	Estimated Growth	Market Cap

5 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: A032620 is good value based on its Price-To-Sales Ratio (1x) compared to the Asian Healthcare Services industry average (5x).

Price to Sales Ratio vs Fair Ratio

What is A032620's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

A032620 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	1x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate A032620's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Ray

₩100.3b

RAY Co., Ltd. provides x-ray diagnostic equipment in the dental industry.

A228670

₩6,470.00

-0.3%

-73.4%

Vieworks

₩200.2b

Develops, manufactures, and sells imaging systems and solutions.

A100120

₩21,800.00

6.3%

-19.1%

Boditech Med

₩347.2b

Offers instruments and diagnostic reagents in South Korea and internationally.

A206640

₩15,800.00

0.1%

-10.4%